Redhill Biopharma Announced The Publication Of Data, In Journal Microorganisms, From The Phase 2/3 Study Of Opaganib In Covid-19 Pneumonia That Showed 62% Reduction In Covid-19 Mortality
Redhill Biopharma Announced The Publication Of Data, In Journal Microorganisms, From The Phase 2/3 Study Of Opaganib In Covid-19 Pneumonia That Showed 62% Reduction In Covid-19 Mortality
redhill生物製藥宣佈，在《微生物》期刊上發表了關於Opaganib在Covid-19肺炎的2/3期研究數據，顯示Covid-19死亡率減少了62%
- Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement in time to room air (no longer needing supplemental oxygen), has been newly published in the peer-reviewed journal, Microorganisms
- The analysis, from a large sub-group of 251 hospitalized, moderately severe COVID-19 patients requiring a fraction of inspired oxygen (FiO2) up to and including 60%, also indicates that FiO2 of greater than 60% may represent a threshold level for disease severity, and may potentially be a patient selection biomarker, an important finding for future therapeutic strategies and studies
- 根據口服奧帕尼布治療COVID-19肺炎的隨機、安慰劑對照、雙盲第2/3期研究的事後分析數據，在同行評審的期刊《微生物》上新近發表，顯示死亡率降低了62%，無需額外吸氧的時間（不再需要輔助氧氣）提高了21%。
- 根據對251名住院的中度重症COVID-19患者進行的大規模子組分析，這些患者需要最高60％的吸氧濃度（FiO2），結果顯示FiO2大於60％可能代表疾病嚴重程度的一個閾值水平，可能成爲患者選擇的生物標誌物，這對於未來的治療策略和研究是一個重要發現。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。